Evidence for octreotide subcutaneously in the treatment of acromegaly

Journal of Endocrinology

Volumn 155, Issue SUPPL. 1, 1997, Pages

  Liuzzi, A ^a   Oppizzi, G ^b  

^a Division of Endocrinology   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE;

ACROMEGALY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; GROWTH HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; DRUG ADMINISTRATION SCHEDULE; EVALUATION STUDIES; HORMONES; HUMANS; INJECTIONS, SUBCUTANEOUS; OCTREOTIDE; SOMATOSTATIN;

EID: 0030870702     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O & Faglia G 1995 Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group. European Journal of Endocrinology 133 430-439.
2. Avagnina P, Martini M, Terzolo M, Sansoe G, Peretti P, Tinivella P, Pia A, Molino G & Angeli A 1996 Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Metabolism: Clinical and Experimental 45 109-113.
3. Barkan A, Lloyd RV & Chandler WP 1988 Pre-operative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism 67 1040-1048.
4. Bates AS, Van't Hoff W, Jones JM & Clayton RN 1993 An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 86 293-299.
5. Chanson P, Timsit J & Masquet C 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine 113 921-925.
6. Dullaart RP, Meijer S, Marbach P & Sluiter WJ 1992 Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. European Journal of Clinical Investigation 22 494-502.
7. Ezzat S, Redelmeier DA, Gnehm M & Harris AG 1995 A prospective multicenter octreotide dose-response study in the treatment of acromegaly. Journal of Endocrinological Investigation 18 364-369.
8. Ezzat S, Snyder PJ, Young F, Bovaiy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA & Melmed S 1992 Octreotide treatment of acromegaly - a randomized multicenter study. Annals of Internal Medicine 117 711-718.
9. Flogstad AK, Halse J, Bakke S, Lancranjan J, Marbach P, Bruns CH & Jervell J 1997 Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism 81 23-28.
10. Fredenrich A, Sosset C, Bernard JL, Sadoul JL & Freychet P 1991 Acute pancreatitis after short-term octreotide. Lancet ii 52-53.
11. Fredstorp L, Kutz K & Werner S 1994 Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clinical Endocrinology 41 103-108.
12. Giustina A, Boni E, Romanelli G, Grassi V & Giustina G 1995 Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. American Journal of Cardiology 75 1042-1047.
13. Hansen TB, Gram J, Bjerre P, Hagen C & Bollerslev J 1994 Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clinical Endocrinology 41 323-329.
14. Ho PJ, Fig LM, Barkan AL & Shapiro B 1992 Bone mineral density of the axial skeleton in acromegaly. Journal of Nuclear Medicine 33 1608-1612.
15. James RA, Chatterjee S & White MC 1989 Continuous infusion of octreotide in acromegaly. Lancet i 1083-1086.
16. Lamberts SWJ, Reubi JC & Krenning EP 1992 Somatostatin analogs in the treatment of acromegaly. Endocrinology and Metabolism Clinics of North America 21 737-752.
17. Leclercq F, Fille A, Albat B, Grolleau R & Jaffiol C. 1993 Dilated cardiomyopathy in acromegaly worsening under octreotide treatment. Apropos of a case. Annales de Cardiologie et d'Angeiologie 42 151-154.
18. Liuzzi A, Dallabonzana D, Oppizzi G & Chiodini PG 1996 The medical treatment of acromegaly with octreotide. In Octreotide from Basic Science to Clinical Medicine, pp 74-89. Ed C Scarpignato. Basel: Karger.
19. Melmed S, Dowling RH, Frohman L, Ho K, Lamberts SWJ, LaMont JT, Sassolas G, Schoenfield L, Snyder PJ & Wass JAH 1994 Acromegaly Therapy Consensus Development Panel. Consensus statement: Benefits versus risks of medical therapy for acromegaly. American Journal of Medicine 97 468-473.
20. Merola B, Cittadini A, Colao A, Fazio S, Sabatini D, Biondi B, Saccà L & Lombardi G 1993 Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. Journal of Clinical Endocrinology and Metabolism 77 790-793.
21. Musolino NR, Marino R Jr & Bronstein MD 1990 Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995. Clinical Journal of Pain 6 243-245.
22. Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M & Hashimoto K 1995 Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocrine Journal 42 385-389.
23. Padayatty SJ, Perrins EJ & Belchetz PE 1996 Octreotide treatment increases exercise capacity in patients with acromegaly. European Journal of Endocrinology 134 554-559.
24. Plöckinger U, Liehr RM & Quabbe HJ 1993 Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-h intragastric pH values. Journal of Clinical Endocrinology and Metabolism 77 157-162.
25. Quabbe HJ & Plöckinger U 1989 Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism 68 873-881.
26. Sassolas G, Harris AG & James-Deidier A 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. Journal of Clinical Endocrinology and Metabolism 71 391-397.
27. Spinas GA, Zapf J, Landolt AM, Stuckmann, G & Froesch ER 1987 Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinologica 114 249-256.
28. Stevanaert A & Beckers A 1996 Presurgical octreotide treatment in acromegaly. Metabolism 45 72-74.
29. Vance ML 1996 Acromegaly: medical treatment. In Pituitary Adenomas, pp 409-416. Eds AM Landolt, ML Vance & PL Reilly. New York: Churchill Livingstone.
30. Vance ML & Harris AG 1991 Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Archives of Internal Medicine 151 1573-1578.
31. Wang C, Lam KS, Arceo E & Chan FL 1989 Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 69 670-677.